Eton Pharmaceuticals, Inc. (ETON): who owns it and who trades it
As of Nov 16, 2026, ETON insiders reported 31 open-market sales worth $31M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sean Brynjelsen (CEO), with $9.9M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Eton Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ETON
166 funds and institutions reported ETON shares worth $768M at the end of Q2 2026, about 78% of the company. The largest holder is Opaleye Management Inc. with 10.5%.
Funds and institutions (13F) 78%Everyone else 22%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Opaleye Management Inc. | 2.86M | 10.48% | $104M | No change |
| Nantahala Capital Management, LLC | 2.35M | 8.62% | $85.1M | +100% |
| EcoR1 Capital, LLC | 2.17M | 7.96% | $78.6M | No change |
| BlackRock, Inc. | 1.90M | 6.95% | $68.6M | +10% |
| Vanguard Capital Management LLC | 976,570 | 3.58% | $35.4M | -2% |
| Morgan Stanley | 767,972 | 2.81% | $27.8M | +61% |
| State Street Corp | 701,786 | 2.57% | $25.4M | +32% |
| Geode Capital Management, LLC | 652,303 | 2.39% | $23.6M | +13% |
| Oberweis Asset Management Inc/ | 501,600 | 1.84% | $18.2M | +14% |
| National Philanthropic Trust | 492,112 | 1.80% | $17.8M | No change |
| Westside Investment Management, Inc. | 431,160 | 1.58% | $15.6M | -8% |
| Pillsbury Lake Capital LLC | 387,157 | 1.42% | $14M | +6% |
| Nuveen, LLC | 375,707 | 1.38% | $13.6M | +548% |
| BNP Paribas Financial Markets | 322,466 | 1.18% | $11.7M | +7% |
| Woodline Partners LP | 310,879 | 1.14% | $11.3M | +82% |
| Thompson Siegel & Walmsley LLC | 297,232 | 1.09% | $10.8M | -27% |
| Northern Trust Corp | 255,849 | 0.94% | $9.3M | +8% |
| Marshall Wace, LLP | 249,182 | 0.91% | $9M | +201% |
| Panoramic Capital, LLC | 208,192 | 0.76% | $7.5M | +13% |
| Vanguard Portfolio Management LLC | 194,591 | 0.71% | $7M | +28% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ETON insiders reported $0 of open-market purchases and $31M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Ipek Erdogan-Trinkaus | Chief Commercial Officer | Sale | 2,340 | $67.18 | $157K | Form 4 |
| Nov 10, 2026 | Ipek Erdogan-Trinkaus | Chief Commercial Officer | Sale | 1,160 | $67.88 | $78.7K | Form 4 |
| Nov 10, 2026 | Charles J Casamento | Director | Sale | 6,380 | $64.33 | $410K | Form 4 |
| Nov 10, 2026 | Charles J Casamento | Director | Sale | 14,715 | $65.32 | $961K | Form 4 |
| Nov 10, 2026 | Charles J Casamento | Director | Sale | 22,601 | $66.26 | $1.5M | Form 4 |
| Nov 10, 2026 | Charles J Casamento | Director | Sale | 33,956 | $67.11 | $2.3M | Form 4 |
| Nov 10, 2026 | Charles J Casamento | Director | Sale | 2,903 | $67.87 | $197K | Form 4 |
| Oct 6, 2026 | David Krempa | Chief Business Officer | Sale | 4,166 | $55.07 | $229K | Form 4 |
| Aug 28, 2026 | Paul V Maier | Director | Sale | 13,485 | $60.21 | $812K | Form 4 |
| Aug 28, 2026 | Paul V Maier | Director | Sale | 128 | $61.77 | $7.9K | Form 4 |
| Aug 28, 2026 | Paul V Maier | Director | Sale | 36,387 | $58.64 | $2.1M | Form 4 |
| Aug 24, 2026 | David Krempa | Chief Business Officer | Sale | 25,000 | $65.07 | $1.6M | Form 4 |
| Aug 20, 2026 | Sean Brynjelsen | CEO | Sale | 7,342 | $62.12 | $456K | Form 4 |
| Aug 20, 2026 | Sean Brynjelsen | CEO | Sale | 36,373 | $61.11 | $2.2M | Form 4 |
| Aug 20, 2026 | Sean Brynjelsen | CEO | Sale | 47,307 | $60.17 | $2.8M | Form 4 |
| Aug 19, 2026 | Sean Brynjelsen | CEO | Sale | 8,978 | $62.65 | $562K | Form 4 |
| Jul 14, 2026 | Opaleye Management Inc. | 10% owner | Sale | 13,315 | $37.54 | $500K | Form 4 |
| Jul 14, 2026 | Opaleye Management Inc. | 10% owner | Sale | 15,000 | $37.54 | $563K | Form 4 |
| Jul 7, 2026 | Opaleye Management Inc. | 10% owner | Sale | 20,000 | $38.37 | $767K | Form 4 |
| Jul 7, 2026 | Opaleye Management Inc. | 10% owner | Sale | 6,685 | $38.37 | $257K | Form 4 |
| Jul 6, 2026 | Opaleye Management Inc. | 10% owner | Sale | 10,000 | $38.00 | $380K | Form 4 |
| Jul 2, 2026 | Opaleye Management Inc. | 10% owner | Sale | 25,000 | $37.39 | $935K | Form 4 |
| Jul 2, 2026 | Opaleye Management Inc. | 10% owner | Sale | 65,000 | $37.39 | $2.4M | Form 4 |
| Jun 17, 2026 | Jennifer McKie Adams | Director | Sale | 50,000 | $32.48 | $1.6M | Form 4 |
| May 28, 2026 | Sean Brynjelsen | CEO | Sale | 148 | $32.67 | $4.8K | Form 4 |
| May 28, 2026 | Sean Brynjelsen | CEO | Sale | 119,852 | $31.88 | $3.8M | Form 4 |
| May 27, 2026 | David Krempa | Chief Business Officer | Sale | 19,679 | $31.47 | $619K | Form 4 |
| May 26, 2026 | David Krempa | Chief Business Officer | Sale | 37,524 | $31.49 | $1.2M | Form 4 |
| May 22, 2026 | David Krempa | Chief Business Officer | Sale | 9,315 | $33.88 | $316K | Form 4 |
| May 22, 2026 | David Krempa | Chief Business Officer | Sale | 519 | $35.00 | $18.2K | Form 4 |
| May 22, 2026 | David Krempa | Chief Business Officer | Sale | 32,963 | $33.22 | $1.1M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sean Brynjelsen | President & CEO, Director | – | $9.9M | Aug 20, 2026 |
| Opaleye Management Inc. | 10% owner | – | $5.8M | Jul 14, 2026 |
| Charles J Casamento | Director | – | $5.3M | Nov 10, 2026 |
| David Krempa | Chief Business Officer | – | $5.1M | Oct 6, 2026 |
| Paul V Maier | Director | – | $3M | Aug 28, 2026 |
| Jennifer McKie Adams | Director | – | $1.6M | Jun 17, 2026 |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer | – | $236K | Nov 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ETON short interest
Moderate short interest. 6.9% of ETON shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 28%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.99M ETON shares were sold short, 6.9% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 365,610 shares, buying them all back would take about 5.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.99M | 6.95% | +2% | 365,610 | 5.4 |
| Oct 15, 2026 | 1.94M | 6.80% | +6% | 588,430 | 3.3 |
| Sep 30, 2026 | 1.83M | 6.42% | +19% | 624,706 | 2.9 |
| Sep 15, 2026 | 1.54M | 5.40% | +14% | 438,622 | 3.5 |
| Aug 31, 2026 | 1.35M | 4.72% | -6% | 681,758 | 2.0 |
| Aug 14, 2026 | 1.43M | 5.00% | +9% | 637,002 | 2.2 |
| Jul 31, 2026 | 1.31M | 4.81% | +7% | 633,128 | 2.1 |
| Jul 15, 2026 | 1.23M | 4.49% | -15% | 405,195 | 3.0 |
| Jun 30, 2026 | 1.45M | 5.31% | +2% | 487,785 | 3.0 |
| Jun 15, 2026 | 1.43M | 5.23% | +13% | 345,181 | 4.1 |
| May 29, 2026 | 1.26M | 4.62% | -19% | 449,611 | 2.8 |
| May 15, 2026 | 1.55M | 5.68% | -5% | 478,036 | 3.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Eton Pharmaceuticals company events
Eton Pharmaceuticals filed 22 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Nov 5, 2026AnnouncementEton Pharmaceuticals, Inc. issued a press release announcing preliminary results from a randomized, double-blind, placebo-controlled pilot study evaluating ET-700, its investigational extended-release zinc acetate formulation being developed for Wilson disease. Filing
- Nov 2, 2026AnnouncementEton Pharmaceuticals, Inc. announced ET-900, a new development program evaluating mecasermin injection for the treatment of infantile and epileptic spasms. Filing
- Oct 14, 2026DealAs disclosed in Item 1.01, on October 13, 2026, the Company entered into an exclusive license agreement and a supply agreement covering the United States and its territories for LIBERVANT® (diazepam) buccal film, an orphan-designated, differentiated treatment for seizure clusters in patients with… Filing
- Sep 28, 2026AnnouncementEton Pharmaceuticals, Inc. issued a press release announcing that it has launched IMPAVIDO® (miltefosine) capsules. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Aug 5, 2026DealAs disclosed in Item 1.01, on July 31, 2026, the Company entered into a license agreement for a late-stage rare disease product candidate, ASN-001 (timolol topical gel), from Auson for the treatment of proliferating superficial infantile hemangiomas. Filing
- Aug 4, 2026LeadershipEton Pharmaceuticals, Inc. appointed Danka Radosavljevic (age 42) as Chief Operating Officer. Filing
- Jul 29, 2026AnnouncementEton Pharmaceuticals, Inc. issued a press release announcing the submission of a prior approval supplement to expand the indication of KHINDIVI® (hydrocortisone) oral solution. Filing
- Jun 9, 2026VoteReported shareholder vote results. Filing
- May 19, 2026DealAs disclosed in Item 1.01, on May 18, 2026, the Company entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) oral capsules with Supplier. Filing
- May 14, 2026ResultsReleased financial results. Filing
- May 1, 2026AnnouncementEton Pharmaceuticals, Inc. issued a press release announcing that it has launched HEMANGEOL® (propranolol) Oral Solution. Filing
- Apr 27, 2026AnnouncementEton Pharmaceuticals, Inc. issued a press release announcing a pilot study underway for product candidate ET-700, the Company's extended-release formulation of zinc acetate, which will be compared to Galzin® and a placebo for the treatment of Wilson disease. Filing
- Apr 16, 2026LeadershipEton Pharmaceuticals, Inc. issued a press release announcing the appointment of Judith Matthews as Executive Vice President, Accounting and Finance. Filing
- Apr 15, 2026AgreementEton Pharmaceuticals, Inc. entered into a sixth amendment to its credit agreement, by and among the Company and SWK Funding LLC. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Mar 2, 2026DealAs disclosed in Item 1.01, on February 27, 2026, the Company entered into a licensing agreement and acquired the U.S. rights to HEMANGEOL® (propranolol) oral solution with Licensor. Filing
- Feb 25, 2026AnnouncementEton Pharmaceuticals, Inc. issued a press release announcing the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for DESMODA™ (desmopressin acetate) Oral Solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency… Filing
- Feb 2, 2026AnnouncementEton Pharmaceuticals, Inc. issued a press release announcing the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Filing
- Dec 4, 2025AnnouncementShared information with investors. Filing
- Nov 18, 2025DealAmended an earlier report. Eton Pharmaceutical, Inc. (the "Company'') filed a Current Report on Form 8-K reporting that on December 1 9, 2024, the Company completed its purchase of Increlex® from Ipsen S.A. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Eton Pharmaceuticals financials
Famous investors that hold ETON
3 of the 50 well-known investors we track reported holding ETON in their latest 13F filing. The largest position is Steve Cohen's, worth $5.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 102,181 | $5.3M | 0.0% | +127% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 33,414 | $1.7M | 0.0% | -32% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 14,459 | $744K | 0.0% | -72% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ETON in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | EcoR1 Capital, LLC | 13G/A | 8.6% |
| Nov 16, 2026 | EcoR1 Capital, LLC | 13G/A | 8.6% |
| Nov 6, 2026 | Opaleye Management Inc. | 13G/A | 8.5% |
| Nov 6, 2026 | Opaleye Management Inc. | 13G/A | 8.5% |
Questions about Eton Pharmaceuticals, Inc. (ETON) stock
Who owns the most ETON stock?
The largest reported owner of Eton Pharmaceuticals, Inc. (ETON) is Opaleye Management Inc., with 10.5% of the company. In total, 166 funds and institutions reported holding ETON at the end of Q2 2026, together about 78% of the shares. See the largest owners.
Are ETON insiders buying or selling?
In the last 12 months, ETON insiders reported no open-market purchases and 31 sales worth $31M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in ETON?
As of Oct 30, 2026, 1.99M ETON shares were sold short, 6.9% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 365,610 shares, buying them all back would take about 5.4 trading days (days to cover). See the history.
Which famous investors hold ETON?
3 of the 50 well-known investors we track reported ETON in their latest 13F filing, including Steve Cohen, Ken Griffin, Jim Simons. The largest position is worth $5.3M. See all holders.
Executive pay
Eton Pharmaceuticals's chief executive was paid a total of $2.9M for the year ended Dec 31, 2025, up 21% from $2.4M the year before. In the last 12 months, Eton Pharmaceuticals's executives and directors bought no stock on the open market and sold $25.2M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.